Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

Phase 2

Completed

Conditions: Chronic Kidney Disease
Inflammation
Cardiovascular Risk

Interventions: Drug: Ziltivekimab
Drug: Placebo (ziltivekimab)

First Posted Date: 2020-11-12

Last Posted Date: 2021-10-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT04626505

Locations: 🇯🇵
Novo Nordisk Investigational Site, Ehime, Japan

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Oral Semaglutide

First Posted Date: 2020-10-26

Last Posted Date: 2024-01-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 194

Registration Number: NCT04601753

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Oral Semaglutide

First Posted Date: 2020-10-26

Last Posted Date: 2024-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 145

Registration Number: NCT04601740

Locations: 🇳🇱
Master Centre Netherlands, Alphen A/d Rijn, Netherlands

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

Phase 3

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (semaglutide)
Drug: Oral semaglutide

First Posted Date: 2020-10-22

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 132

Registration Number: NCT04596631

Locations: 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
Nemours Chld Clnc Jacksonville, Jacksonville, Florida, United States
🇺🇸
Nemours Children's Health, Pensacola, Florida, United States

and more 67 locations

A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec

First Posted Date: 2020-10-22

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT04597697

Locations: 🇸🇰
Summit Clinical Research s.r.o., Bratislava, Slovakia
🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Drug: Faster aspart
Drug: Insulin aspart
Drug: Insulin degludec

First Posted Date: 2020-10-19

Last Posted Date: 2024-03-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 331

Registration Number: NCT04588259

Locations: 🇨🇳
Chongqing University Three Gorges Hospital, ChongQing, Chongqing, China
🇨🇳
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
🇨🇳
Nanjing Jiangning Hospital, Nanjing, Jiangsu, China

and more 33 locations

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities

Completed

Conditions: Haemophilia A

Interventions: Drug: Turoctocog alfa

First Posted Date: 2020-10-14

Last Posted Date: 2023-11-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT04584892

Locations: 🇮🇹
Novo Nordisk Investigational Site, Vicenza, Italy

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Icodec

First Posted Date: 2020-10-09

Last Posted Date: 2023-09-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT04582435

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec

First Posted Date: 2020-10-09

Last Posted Date: 2023-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT04582448

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

A Study of FT-7051 in Men With MCRPC

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: FT-7051

First Posted Date: 2020-10-05

Last Posted Date: 2023-08-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT04575766

Locations: 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸
University of Colorado Health, Aurora, Colorado, United States

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy